Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ixekizumab treatment of patients with moderate-to-severe plaque psoriasis.

ABSTRACT: Ixekizumab treatment of patients with moderate-to-severe plaque psoriasis.

PROVIDER: PRJNA737931 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Ixekizumab treatment of patients with moderate-to-severe plaque psoriasis.

Project description:Objectives: To asses skin clearance and patient-reported outcomes for ixekizumab treatment. Methods: IXORA-R enrolled adults with moderate-to-severe plaque psoriasis, defined as static Physician’s Global Assessment ≥ 3, PASI ≥ 12 and involved body surface area ≥ 10%. The trial was registered with ClinicalTrials.gov (NCT03573323).

2023-04-10 | GSE178228 | GEO

Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis

Project description:A gene expression profiling sub-study was conducted in which skin biopsy samples were collected from 85 patients with moderate-to-severe psoriasis who were participating in ACCEPT, an IRB-approved Phase 3, multicenter, randomized trial. This analysis identified 4,175 probe-sets as being significantly modulated in psoriasis lesions (LS) compared with matched biopsies of non-lesional (NL) skin. Skin biopsy samples (n=170) were collected at baseline for RNA extraction and microarray analysis from 85 patients with moderate-to-severe psoriasis without receiving active psoriasis therapy.

2012-07-25 | E-GEOD-30999 | biostudies-arrayexpress

Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis

2012-07-26 | GSE30999 | GEO

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

Project description:A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients. Skin biopsy samples (n=59, LS: lesion, NL: non-lesion) were collected at baseline, weeks 1 and 12 following guselkumab treatment from patients with moderate-to-severe psoriasis for RNA extraction and microarray analysis.

2014-05-14 | E-GEOD-51440 | biostudies-arrayexpress

Circulating Monocytes are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast

Project description:Circulating Monocytes are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast

| PRJNA1078849 | ENA

Skin expression data from psoriasis patients treated with IL-17A inhibitor

Project description:Psoriasis is a chronic, recurrent, inflammatory systemic disease that affects approximately 2-3% of the population worldwide. IL-17A plays a key pathogenic role in psoriasis, and IL-17A antigen have emerged as first-line agents for the treatment of moderate-to-severe plaque psoriasis.However, the associated mechanism underlying treatment-associated adverse and psoriasis relapse has not been reported

2025-08-27 | GSE212476 | GEO

Cross-sectional study of proteomic differences between moderate and severe psoriasis

Project description:Background: Although there is an ongoing understanding of psoriasis vulgaris (PV) pathogenesis, little is known about the proteomic diversity of psoriatic lesions between moderate and severe psoriasis. Objective: To evaluate the proteomic differences between moderate and severe psoriasis and determine biomarkers associated with disease severity. Methods: In this cross-sectional study, we report a proteomic analysis of psoriatic lesions from patients with severe PV (sPV group, n=7) using data-independent acquisition mass spectrometry (DIA-MS), as compared with patients with moderate psoriasis (mPV group, n=8). Results: 173 differentially expressed proteins (DEPs) were significantly differentially expressed between the sPV and mPV groups. Among them, 85 proteins were upregulated, while 88 were downregulated (FC ≥±1.5, P <0.05). Eighteen DEPs were mainly enriched in the IL−17 signalling pathway, Neutrophil extracellular trap formation, Neutrophil degranulation and NF−kappa B signalling pathway, which were associated with psoriasis pathogenesis. Ingenuity pathway (IPA) analysis identified TNF and TDP53 as the top upstream up-regulators, while Lipopolysaccharide and YAP1 were the top potential down-regulators. The main active pathways were antimicrobial peptides and PTEN signalling, while the inhibitory pathways were the neutrophil extracellular trap pathway, neutrophil degranulation, and IL-8 signalling. 4D-parallel reaction monitoring (4D-PRM) analysis suggested that KRT6A were downregulated in sPV.

2024-06-06 | PXD052886 |

Genome-wide DNA methylation analysis of peripheral blood samples of moderate-to-severe psoriasis patients treated with anti-TNF drugs

Project description:Genome wide DNA methylation profiling of peripheral blood samples of moderate-to-severe psoriasis patients treated with anti-TNF drugs. Patients were distributed on Excellent Responders (ER) if they achieved PASI90 (a 90% reduction with respect to baseline PASI) at 3 and 6 months of treatment with anti-TNF drugs and Partial responders if they did not achieve a PASI75 (a 75% reduction with respect to baseline PASI) at 3 and 6 months of treatment. The Illumina Infinium 450k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 485,000 CpGs in 49 ER and 21 PR which were obtained from peripheral blood samples of anti-TNF drug treated patients. We have searched for pharmaoepigenetic biomarkers of anti-TNF response in moderate-to-severe psoriasis patients.

2020-05-28 | GSE151278 | GEO

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

2014-05-14 | GSE51440 | GEO

Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis

Project description:Here we elucidate the molecular mechanism of tofacitinib, an oral Janus kinase inhibitor, in psoriasis. Tofacitinib exhibits a multi-tiered action, with early direct effects on keratinocytes and histological and transcriptomic improvement prior to IL-17 reduction. Twelve patients with plaque psoriasis were randomized (3:1) to receive tofacitinib 10Â mg or placebo twice daily for 12 weeks. Biopsies were taken from lesional and nonâlesional skin at baseline, and from lesional skin on Day 1, Day 3, and Weeks 1, 2, 4 and 12. Biopsies were examined for psoriatic epidermal features (thickness; Ki67+ keratinocytes, keratin 16 [KRT16] mRNA expression; phosphoSTAT [pSTAT] + nuclei) and T-cell and dendritic cell (DC) subsets using immunohistochemistry. mRNA transcripts were quantified by microarray.

2016-06-30 | E-GEOD-69967 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data